Anna-Marie Bloch Münster

Medicine & Life Sciences

1. Anticoagulants 100%
2. Dabigatran 83%
3. Fibrin 79%
4. Klinefelter Syndrome 75%
5. Venous Thromboembolism 65%
6. Cohort Studies 59%
7. Venous Thrombosis 56%
8. Thrombin 54%
9. Hemorrhage 54%
10. Ischemic Preconditioning 49%
11. Fibrinolysis 48%
12. International Normalized Ratio 45%
13. Hip Fractures 44%
14. Testosterone 40%
15. Atrial Fibrillation 38%
16. Urokinase-Type Plasminogen Activator 38%
17. Hepacivirus 38%
18. Fibrinogen 36%
19. Testosterone Congeners 35%
20. Plasminogen Activators 32%
21. Thrombosis 30%
22. lipoprotein-associated coagulation inhibitor 29%
23. Therapeutics 29%
24. Warfarin 28%
25. Hepatitis C 28%
26. Randomized Controlled Trials 27%
27. Mortality 27%
28. Rivaroxaban 25%
29. Multicenter Studies 24%
30. Serum 24%
31. Protein S 24%
32. idarucizumab 23%
33. Brain Concussion 22%
34. Peptide Hydrolases 22%
35. Protein-Arginine Deiminases 22%
36. Myocardial Ischemic Preconditioning 22%
37. Population 22%
38. nintedanib 21%
39. Citrullination 21%
40. Colorectal Neoplasms 21%
41. Swine 21%
42. Bence Jones Protein 21%
43. Factor VII 21%
44. IgA receptor 20%
45. Antifibrinolytic Agents 20%
46. Wounds and Injuries 20%
47. Confidence Intervals 20%
48. Virus Diseases 20%
49. Calcium-Binding Proteins 19%
50. Pregnancy-Associated alpha 2-Macroglobulins 19%